uniQure (NASDAQ:QURE) Shares Down 6.7% – What’s Next?

uniQure (NASDAQ:QURE)’s stock price was down 6.7% during mid-day trading on Thursday . The company traded as low as $14.30 and last traded at $14.60. Approximately 456,913 shares changed hands during trading, a decline of 72% from the average daily volume of 1,633,786 shares. The stock had previously closed at $15.65.

Analysts Set New Price Targets

A number of research firms have commented on QURE. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Wednesday. Leerink Partners increased their price objective on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Guggenheim restated a “buy” rating on shares of uniQure in a research note on Wednesday. Finally, Cantor Fitzgerald raised their price target on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $32.14.

uniQure Stock Up 2.3 %

The business has a 50-day simple moving average of $6.85 and a 200-day simple moving average of $6.28. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market cap of $750.60 million, a price-to-earnings ratio of -3.10 and a beta of 0.89.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. On average, equities analysts anticipate that uniQure will post -3.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.74% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Institutional investors have recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC grew its position in uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares during the last quarter. Geode Capital Management LLC increased its position in uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after acquiring an additional 6,362 shares during the period. American Century Companies Inc. raised its stake in uniQure by 14.6% during the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after acquiring an additional 8,642 shares during the last quarter. Finally, RTW Investments LP acquired a new stake in uniQure during the 3rd quarter worth approximately $49,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.